Lexaria Bioscience Corp.
LEXXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Dec 26, 2025 | H.C. Wainwright | Yi Chen | $1.50(+168%) | $0.56 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Dec 26, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jul 29, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jul 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 24, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 2, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 25, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 18, 2024 |
| Maxim Group | maintain | Buy | Mar 5, 2024 |
Earnings History
Next report: Nov 24, 2026 · EPS est. $-0.90| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Jul 13, 2026 | $-1.20 | $-0.90 | — | $50.0K |
| Apr 13, 2026 | $-0.90 | $-1.05 | $20.0K | $50.0K |
| Jan 13, 2026 | $-1.05 | $-1.95 | — | $100.0K |
| Nov 26, 2025 | $-2.10 | $-2.40 | $200.0K | $137.0K |
| Jul 14, 2025 | $-3.15 | $-2.25 | $174.0K | $137.0K |
| Apr 14, 2025 | $-2.25 | $-2.40 | $174.0K | $150.0K |
| Jan 10, 2025 | $-2.40 | $-1.80 | $184.0K | $100.0K |
| Nov 26, 2024 | $-2.25 | $-1.65 | $92.0K | $200.0K |
News
Third pharmaceutical company relationship entered Kelowna, British Columbia – November 4, 2026 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an unnamed pharmaceutical company (“ PharmCo ”) to investigate Lexaria's DehydraTECH technology with one or more proprietary PharmCo molecules.
New patents awarded in the US, Canada, and Europe IP protection for treatments for Epilepsy, Diabetes, and Hypertension
Kelowna, BC – October 21, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) which is evaluating two oral DehydraTECH-semaglutide (“DHT-sema”) compositions against Novo's® commercially available Wegovy® tablets, over a 5-week duration (the “ Study ”). The final Study arm was fully enrolled a…
KELOWNA, BC / ACCESS Newswire / October 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) which is evaluating two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo's® commercially available Wegovy® tablets, over a 5-week duration (the "Study"). The final Study arm was fully enrolled an…
Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the "Study") that evaluated a number of formulation enhancements using both DehydraTECH-CBD ("DHT-CBD") compositions and DehydraTECH-semaglutide ("DHT-SEMA") glucagon-like pepti…
Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD Kelowna, BC – October 15, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the “ Study ”) that evaluated a number of formulation enhancements using both DehydraTECH-CBD (“ DHT-CBD ”) compositions and DehydraTECH-semaglutide (“ DHT-SEMA ”) glucagon-like …
Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034 Novo announces additional weight-loss in patients switching from injected to oral delivery
Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034 Novo announces additional weight-loss in patients switching from injected to oral delivery KELOWNA, BC / ACCESS Newswire / October 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this strategic update. Lexaria's DehydraTECH™ technology is currently being evaluated both by Lexaria and pharmaceutical industry partners for …
KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update. Lexaria is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at US$12.92/share.
Kelowna, British Columbia – September 17, 2026 - TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is providing the following update. Lexaria is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at US$12.92/share. The combined net proceeds from these two items totaled US$7.9 million. With only 2.1 million shares currently issued and outst…
KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.90 per s…
Kelowna, British Columbia – September 9, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $4…
KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, ha…
Kelowna, British Columbia – TheNewswire - September 8 , 2026 - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024…
Kelowna, British Columbia – September 4 , 2026 - TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms , announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14 th through September 16 th , 2026 in New York City. Richard Christopher, CEO of Lexaria Bioscience Corp, will deliver a company presentation and be available for one-on-one investor meet…
Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate Kelowna, British Columbia – September 1 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms , is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary company, Lexaria (AU) Pty L…
Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary company, Lexaria (AU) Pty Ltd.
Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated Findings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs KELOWNA, BC / ACCES…
Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio Ltd. Here's what investors need to know.
Kelowna, British Columbia – TheNewswire - August 13, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement (“ MTA ”) with Pegbio Co., Ltd (“ PegBio ”) to investigate Lexaria's DehydraTECH technology with a proprietary PegBio molecule under development for the GLP-1 industry. Today's announcement is separate from, and has no relationship with, Lexaria's pre-ex…